Table 1.
Baseline Characteristics of (Non)-Hodgkin Lymphoma Survivors Compared With Healthy Control Subjects
| Healthy Control Subjects (n = 40) | Lymphoma Survivors (n = 80) | P Value | |
|---|---|---|---|
| Demographics | |||
| Age at CMR (y) | 47 ± 11 | 47 ± 11 | 0.92 |
| Male | 21 (53) | 43 (54) | 0.90 |
| Body mass index (kg/m2) | 24 (22-25) | 25 (22-29) | 0.065 |
| Heart rate (beats/min) | 58 (54-64) | 76 (78-84) | <0.001 |
| Systolic blood pressure (mm Hg) | 130 ± 17 | ||
| Diastolic blood pressure (mm Hg) | 81 ± 10 | ||
| Diagnosis | |||
| Hodgkin | 78 (98) | ||
| Mediastinal non-Hodgkin | 2 (3) | ||
| Duration between diagnosis and CMR (y) | 20 ± 8 | ||
| Stage | |||
| I | 8 (10) | ||
| II | 59 (74) | ||
| III | 12 (15) | ||
| IV | 1 (1) | ||
| Gradea | |||
| Favorable | 24 (30) | ||
| Unfavorable | 38 (48) | ||
| Unknown | 18 (23) | ||
| Previous therapy for lymphomas | |||
| First chemotherapy treatment | 72 (90) | ||
| First chemotherapy regimen | |||
| AVBD | 32 (40) | ||
| AVBD + DHAP + MOPP | 1 (1) | ||
| BEACOPP | 2 (3) | ||
| CHOP | 1 (1) | ||
| CHOP + MOPP/AVB(D) | 2 (3) | ||
| EVBP | 8 (10) | ||
| EVBP + MOPP | 1 (1) | ||
| MOPP | 2 (3) | ||
| MOPP/AVB(D) | 23 (29) | ||
| Secondary chemotherapy treatment | 6 (8) | ||
| Secondary chemotherapy regimen | |||
| DHAP | 3 (4) | ||
| MOPP | 2 (3) | ||
| MOPP/AVB | 1 (1) | ||
| Anthracycline-containing chemotherapy | 70 (88) | ||
| High-dose anthracycline–containing chemotherapyb | 12 (15) | ||
| Mediastinal radiotherapy | 80 (100) | ||
| Mediastinal radiotherapy boost | 12 (15) | ||
| Total mediastinal doses (Gy) | 36 (36-40) | ||
| Cardiovascular risk factors and comorbidities | |||
| Diabetes mellitus | 3 (4) | ||
| Hypertension | 13 (16) | ||
| Hyperlipidemia | 10 (13) | ||
| Tobacco use | |||
| Current smoker | 3 (4) | ||
| Former smoker | 22 (28) | ||
| Known coronary artery disease | 0 (0) | ||
| Hypothyroidism | 25 (31) | ||
| Hyperthyroidism | 3 (4) | ||
| Symptoms | |||
| Chest pain | 2 (3) | ||
| Dyspnea on exertion | 8 (10) | ||
| Medications | |||
| Angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker | 10 (13) | ||
| β-blocker | 4 (5) | ||
| Calcium-channel blockers | 3 (4) | ||
| Diuretics | 7 (9) | ||
| Statins | 13 (16) | ||
| Anticoagulation | |||
| Aspirin | 5 (6) | ||
| Coumarin derivates | 2 (3) | ||
| Laboratory results | |||
| Estimated glomerular filtration rate (mL/min/1.73 m2) | 90 (83-96) | ||
| NT-proBNP (pg/ml) | 93 (51-169) |
Values are mean ± SD, n (%), or median (interquartile range).
AVB(D) = Adriamycin (doxorubicin), vincristine, bleomycin (dacarbazine); BEACOPP = bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, vincristine, procarbazine, prednisone; CHOP = cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone; CMR = cardiovascular magnetic resonance; DHAP = dexamethasone, cytarabine, cisplatin; EBVP = epirubicin, bleomycin, vinblastine, prednisone; MOPP = mitoxantrone, vincristine, procarbazine, prednisone; NT-proBNP = N-terminal pro–B-type natriuretic peptide.
Grades are defined according to the European Organization for Research and Treatment of Cancer risk classification for supradiaphragm stadium I and II Hodgkin lymphoma.
High-dose anthracycline: doxorubicin ≥300 mg/m2, epirubicin ≥540 mg/m2, or mitoxantrone ≥90 mg/m2.